Daphnetin, a Coumarin with Anticancer Potential against Human Melanoma: In Vitro Study of Its Effective Combination with Selected Cytostatic Drugs
Author:
Wróblewska-Łuczka Paula1ORCID, Góralczyk Agnieszka1ORCID, Łuszczki Jarogniew J.1ORCID
Affiliation:
1. Department of Occupational Medicine, Medical University of Lublin, ul. Jaczewskiego 8b, 20-090 Lublin, Poland
Abstract
(1) The treatment of metastatic or drug-resistant melanoma is still a significant therapeutic problem. The aim of this study was to evaluate the anticancer potential of daphnetin (7,8-dihydroxycoumarin) and its combinations with five different cytostatic drugs (mitoxantrone, docetaxel, vemurafenib, epirubicin and cisplatin). (2) The viability, proliferation and cytotoxicity of daphnetin against four human malignant melanoma cell lines were evaluated. The interactions were assessed using isobolographic analysis for the combinations of daphnetin with each of the five cytostatic drugs. (3) Daphnetin showed anticancer activity against malignant melanoma, with IC50 values ranging from 40.48 ± 10.90 µM to 183.97 ± 18.82 µM, depending on the cell line. The combination of daphnetin with either vemurafenib or epirubicin showed an antagonistic interaction. Moreover, additive interactions were observed for the combinations of daphnetin with cisplatin and docetaxel. The most desirable synergistic interactions for human melanoma metastatic cell lines were observed for the combination of daphnetin with mitoxantrone. (4) The obtained results suggest that daphnetin should not be combined with vemurafenib or epirubicin in the treatment of malignant melanoma due to the abolition of their anticancer effects. The combination of daphnetin with mitoxantrone is beneficial in the treatment of metastatic melanoma due to their synergistic interaction.
Funder
Medical University of Lublin, Poland
Reference50 articles.
1. Zob, D.L., Augustin, I., Caba, L., Panzaru, M.C., Popa, S., Popa, A.D., Florea, L., and Gorduza, E.V. (2022). Genomics and Epigenomics in the Molecular Biology of Melanoma-A Prerequisite for Biomarkers Studies. Int. J. Mol. Sci., 24. 2. Lorenz, A., Kozłowski, M., Lenkiewicz, S., Kwiatkowski, S., and Cymbaluk-Płoska, A. (2022). Cutaneous Melanoma versus Vulvovaginal Melanoma—Risk Factors, Pathogenesis and Comparison of Immunotherapy Efficacy. Cancers, 14. 3. Melanoma Risk Factors and Prevention;Dzwierzynski;Clin. Plast. Surg.,2021 4. Lopes, J., Rodrigues, C.M.P., Gaspar, M.M., and Reis, C.P. (2022). Melanoma Management: From Epidemiology to Treatment and Latest Advances. Cancers, 14. 5. Villani, A., Potestio, L., Fabbrocini, G., Troncone, G., Malapelle, U., and Scalvenzi, M. (2022). The Treatment of Advanced Melanoma: Therapeutic Update. Int. J. Mol. Sci., 23.
Cited by
1 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
|
|